DS-5141

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
Endpoints
Wed, 04/25/18 - 09:50 am
Daiichi Sankyo
Duchenne Muscular Dystrophy
DS-5141